CLINICAL_TRIALS
trial_result
· 2025-05-15
Clinical Trial Update: Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension [Phase 2]
Summary
Phase 2 study of the investigational drug LTP001 in pulmonary arterial hypertension was terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2025-05-15